Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Taspoglutide: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 18:44, 9 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 460517999 of page Taspoglutide for the Chem/Drugbox validation project (updated: 'CAS_number').  Latest revision as of 06:48, 8 December 2023 edit JJMC89 bot III (talk | contribs)Bots, Administrators3,685,221 editsm Moving Category:Glucagon-like peptide-1 receptor agonists to Category:GLP-1 receptor agonists per Misplaced Pages:Categories for discussion/Speedy 
Line 1: Line 1:
{{short description|Chemical compound}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{Use dmy dates|date=June 2020}}
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 448215277 | verifiedrevid = 470477813
⚫ <!-- Clinical data -->

⚫ <!--Clinical data-->
| tradename = | tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| routes_of_administration = ] | routes_of_administration = ]
⚫ <!-- Pharmacokinetic data -->

⚫ <!--Pharmacokinetic data-->
| bioavailability = N/A | bioavailability = N/A
⚫ <!-- Identifiers -->

⚫ | CAS_number_Ref = {{cascite|changed|??}}
⚫ <!--Identifiers-->
⚫ | CAS_number = 275371-94-3
⚫ | CAS_number_Ref = {{cascite|correct|??}}
⚫ | CAS_number = <!-- blanked - oldvalue: 275371-94-3 -->
| ATC_prefix = none | ATC_prefix = none
| PubChem = 56842233
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2PHK27IP3B | UNII = 2PHK27IP3B
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = NA | ChemSpiderID = 32819947
| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D09723
<!--Chemical data--> <!-- Chemical data -->
| C=152 | H=232 | N=40 | O=45 | C=152 | H=232 | N=40 | O=45
| molecular_weight = 3339.75 g/mol
}} }}
'''Taspoglutide''' is a former ], a ] (GLP-1 agonist), that was under investigation for treatment of ] and being codeveloped by ] and ].<ref>{{cite news |url=http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_10/ai_n25492242 |title=Ipsen: Roche Moves Investigational Diabetes Drug, Taspoglutide, into Phase III Clinical Trials |date = June 2008| work=Business Wire}}</ref>
<ref>{{cite web |url=http://www.bio-medicine.org/medicine-technology-1/Roche-Moves-Investigational-Diabetes-Drug--Taspoglutide--Into-Phase-III-Clinical-Trials-2379-1/ |title=Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials |date=June 2008 |access-date=13 January 2009 |archive-date=3 March 2016 |archive-url=https://web.archive.org/web/20160303191454/http://www.bio-medicine.org/medicine-technology-1/Roche-Moves-Investigational-Diabetes-Drug--Taspoglutide--Into-Phase-III-Clinical-Trials-2379-1/ |url-status=dead }}</ref>

Initially, phase II trials reported it was effective and well tolerated.<ref name=Baggio2008>{{cite web | vauthors = Baggio LL, Drucker DJ |url=http://www.medscape.com/viewarticle/578304 |title=Glucagon-like Peptide-1 Analogs Other Than Exenatide |year=2008 }}</ref>

Of the eight planned phase III clinical trials of weekly taspoglutide (four against ], ], ], and ]), at least five were active in 2009.<ref>{{cite web |url= http://www.medicalnewstoday.com/articles/169171.php |title= Ipsen's Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint in the First Phase III Clinical Trial |date= October 2009 |access-date= 12 February 2010 |archive-date= 1 March 2010 |archive-url= https://web.archive.org/web/20100301202923/http://www.medicalnewstoday.com/articles/169171.php |url-status= dead }}</ref> Preliminary results in early 2010 were favourable.<ref>{{cite web |url=http://www.genengnews.com/news/bnitem.aspx?name=75286047 |title=Roche Reports Positive Data from Five Phase III Trials of Type 2 Diabetes Therapy |date=February 2010}}</ref> (At least one of the eight planned phase III trials had not started recruiting by end 2009.<ref>{{ClinicalTrialsGov|NCT01051011|A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy}}</ref>)

In September 2010 Roche halted Phase III clinical trials due to instances of serious hypersensitivity reactions and gastrointestinal side effects.<ref>{{cite web |url=http://www.medpagetoday.com/Endocrinology/Diabetes/22139 |title=Roche Halts Trials of Taspoglutide |date=13 September 2010 }}</ref><ref>{{cite web |url=http://www.medicalnewstoday.com/articles/200893.php |title=Experimental Diabetes Drug Taspoglutide Late-Stage Trials Suspended |date=13 September 2010 }}</ref>

{{As of|May 2022}} no new trials have been registered since 2010.<ref></ref>

==Chemistry==
Taspoglutide is the peptide with the sequence H<sub>2</sub>N-His-2-methyl-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-2-methyl-Ala-Arg-CONH<sub>2</sub>.

In other words, it is the 8-(2-methylalanine)-35-(2-methylalanine)-36-<small>L</small>-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.

==See also==
* ]

==References==
{{reflist}}

{{Oral hypoglycemics and insulin analogs}}

]
]
]


{{gastrointestinal-drug-stub}}